The emergence of mephedrone and various synthetic cathinones has offered difficulties for lawmakers and regulatory businesses tasked with controlling the proliferation of new psychoactive substances. The dynamic character of artificial drug production, coupled with the power of chemists to change molecular buildings to evade legal limitations, comp